Rankings
▼
Calendar
TSHA Q1 2025 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
$1B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-32.5% YoY
Gross Profit
$2M
100.0% margin
Operating Income
-$21M
-930.5% margin
Net Income
-$22M
-935.2% margin
EPS (Diluted)
$-0.08
QoQ Revenue Growth
+13.8%
Cash Flow
Operating Cash Flow
-$22M
Free Cash Flow
-$22M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$138M
Total Liabilities
$83M
Stockholders' Equity
$55M
Cash & Equivalents
$117M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$3M
-32.5%
Gross Profit
$2M
$3M
-32.5%
Operating Income
-$21M
-$24M
+12.0%
Net Income
-$22M
-$24M
+10.5%
← Q4 2024
All Quarters
Q2 2025 →